Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 7/20 | 0.53 |
| ▸ | THRB | P10828 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24619767 | 0.97 | LMNA (0.62) | LMNATP53MAPTTHRBPOLB | |
| Formic Acid SCHEMBL29925647 | 0.83 | LMNA (0.64) | LMNATP53MAPTTHRBPOLB | |
| Formic Acid SCHEMBL29925480 | 0.81 | MAPT (0.58) | LMNATP53MAPTTHRBPOLB | |
| SCHEMBL24741269 | 0.80 | LMNA (0.68) | LMNATP53MAPTTHRBPOLB | |
| SCHEMBL24741290 | 0.79 | LMNA (0.67) | LMNATP53MAPTTHRBPOLB | |
| Formic Acid SCHEMBL29925406 | 0.79 | LMNA (0.55) | LMNATP53MAPTTHRBPOLB | |
| SCHEMBL24619803 | 0.79 | LMNA (0.68) | LMNATP53MAPTTHRBPOLB | |
| SCHEMBL24619719 | 0.79 | LMNA (0.68) | LMNATP53MAPTTHRBRXFP1 | |
| SCHEMBL24619396 | 0.79 | TP53 (0.73) | LMNATP53MAPTTHRBPOLB | |
| Formic Acid SCHEMBL29924881 | 0.79 | LMNA (0.63) | LMNATP53MAPTTHRBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4274569-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-11-24 | — | — | US | disclosed |
| WO-2022150316-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | LMNA 1484/4885TP53 96/4885MAPT 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.